Connect Biopharma Announces Long-Term Data From The Maintenance Period Through Week 48 Of CN002 Phase 2 Icanbelimod Trial In Patients With Moderate-To-Severe Ulcerative Colitis
Portfolio Pulse from Happy Mohamed
Connect Biopharma announces positive long-term data from the maintenance period through Week 48 of CN002 Phase 2 Icanbelimod trial in patients with moderate-to-severe ulcerative colitis. Icanbelimod demonstrated sustained clinical remission in 80% of patients and continued to be well-tolerated.
June 01, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Connect Biopharma's Icanbelimod shows positive long-term data in Phase 2 trial for ulcerative colitis, potentially leading to increased interest in the company's stock.
The positive long-term data from the Phase 2 trial of Icanbelimod in patients with moderate-to-severe ulcerative colitis demonstrates the potential of the drug to be an effective treatment option. This could lead to increased interest in Connect Biopharma's stock as investors may see the potential for future growth and revenue from the drug's development and eventual commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100